β-Adrenergic Blocking Agents in Heart Failure: Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials
暂无分享,去创建一个
Eduard Diogène | X. Vidal | E. Galve | E. Diògene | A. Agustí | J. Laporte | Joan-Ramon Laporte | Xavier Vidal | Sara Bonet | Antònia Agustí | Josep Maria Arnau | Enrique Galve | J. Arnau | S. Bonet
[1] P. Simpson,et al. Statistical methods in cancer research , 2001, Journal of surgical oncology.
[2] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[3] M. Packer,et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.
[4] H. Krum. Beta-adrenoceptor blockers in chronic heart failure--a review. , 2003, British journal of clinical pharmacology.
[5] W. Aronow,et al. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. , 1997, The American journal of cardiology.
[6] P. Heidenreich,et al. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. , 1997, Journal of the American College of Cardiology.
[7] R. Doughty,et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.
[8] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[9] Australia.. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.
[10] D E Grobbee,et al. The epidemiology of heart failure. , 1997, European heart journal.
[11] S. Gottlieb,et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.
[12] J. A. Bowers,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.
[13] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.
[14] M. Pfeffer,et al. Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.
[15] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[16] K. Swedberg,et al. Carvedilol for heart failure, with care , 1996, The Lancet.
[17] S. Yamada,et al. A sustained increase in β-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy , 1996 .
[18] M. Kukin,et al. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. , 1996, The American journal of cardiology.
[19] J. Cohn,et al. Effect of carvedilol in severe chronic heart failure , 1996 .
[20] M. Steinfath,et al. Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure , 1996, European Journal of Clinical Pharmacology.
[21] J. Sanderson,et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. , 1995, British heart journal.
[22] J. Bayón,et al. [The effect of gallopamil and propranolol in patients with ischemic cardiopathy and moderate depression of ventricular function]. , 1995, Revista espanola de cardiologia.
[23] H. Krum,et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.
[24] L. Erhardt,et al. Effects of receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol , 2022 .
[25] D. Renlund,et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.
[26] S. Ogawa,et al. Beta-1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for idiopathic dilated cardiomyopathy. , 1995, Cardiology.
[27] M. Metra,et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.
[28] P. Grayburn,et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.
[29] L. Wilkins. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.
[30] W. French,et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.
[31] Diana B. Petitti,et al. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .
[32] G. Plotnick,et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.
[33] J. McMurray,et al. Fortnightly Review: Diagnosis and management of heart failure , 1994, BMJ.
[34] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[35] M. Brown,et al. Beta adrenoreceptor subtype cross regulation in the human heart. , 1993, British heart journal.
[36] J. Skoularigis,et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.
[37] M. Packer,et al. Pathophysiology of chronic heart failure , 1992, The Lancet.
[38] M. Komajda,et al. [Non invasive evaluation of cardiovascular effects of nebivolol in patients with cardiac insufficiency]. , 1992, Archives des maladies du coeur et des vaisseaux.
[39] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[40] G. Paolisso,et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure , 1992 .
[41] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[42] S. G. Pollock,et al. Usefulness of bucindolol in congestive heart failure. , 1990, The American journal of cardiology.
[43] D. Renlund,et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.
[44] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[45] R. Byington,et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.
[46] R. Gunnar,et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.
[47] J. Anderson,et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. , 1985, The American journal of cardiology.
[48] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[49] J. Federman,et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.
[50] J. Schlesselman,et al. Case-Control Studies: Design, Conduct, Analysis , 1982 .
[51] H. Ikram,et al. DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.
[52] N. Dhalla,et al. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. , 1981, American heart journal.
[53] J. A. Thomas,et al. Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.
[54] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.